It's on the expensive end if you're just looking at sales
But take into account the growth rate, cashflow breakeven, they own the IP, c.+60% PCP sales growth in just Australia with expansion beginning.
Yes, it's expensive on paper but there's little need for capital raising (though I think they will still raise at some point) which only leaves on-market buying if you're an institution or fund, with more than 1 years vision, wanting a piece
Ann: Quarterly Activities & Cashflow Report, page-7
Add BIO (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
-0.010(3.13%) |
Mkt cap ! $65.97M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 32.0¢ | 31.0¢ | $6.98K | 22.51K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 42422 | 30.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.0¢ | 430 | 1 |
View Market Depth
| Last trade - 15.43pm 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
30.5¢ |
Change
-0.010 ( 4.69 %) |
||||
| Open | High | Low | Volume | ||
| 31.0¢ | 31.0¢ | 30.5¢ | 30523 | ||
| Last updated 15.47pm 17/05/2024 ? | |||||
| BIO (ASX) Chart |